- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Bradley Monk, MD, FACOG, FACS, professor at the University of Arizona and Creighton University in Phoenix and clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Transcript
In your experience, who are the patients who fare best with PARP inhibitors for ovarian cancer?
The first randomized trials to show efficacy of PARP inhibitors were these 3 maintenance treatments in recurrent ovarian cancer, and olaparib has 2 studies, Study 19 and SOLO2; niraparib of has one, NOVA; and then rucaparib has 1, ARIEL3. And so you can now use PARP inhibitors in treatment in recurrent ovarian cancer based on level 1 randomized trial data, if the patient responds to platinum, across all biomarker subgroups, because response to platinum in the recurrent setting is the biomarker. So again, if you treat a patient in platinum-sensitive relapse with carboplatin-paclitaxel, or carboplatin-liposomal doxorubicin, or even carboplatin-gemcitabine, if she responds, you can keep her in response with either olaparib, rucaparib, or niraparib without sort of ruining the patient experience. All of those studies have no decrement in patient reported outcomes, and no new safety signals identified.
Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care
February 5th 2025While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Read More
Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer
February 3rd 2025While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.
Read More
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
January 28th 2025First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Read More
Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care
January 23rd 2025Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.
Read More
Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends
January 21st 2025Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.
Read More
